Index of drugs

Table. enteric-coated 20 mg: Treatment of mild form of reflux oesophagitis and related symptoms of dyspepsia. Long-term treatment and prevention of recurrent reflux oesophagitis. Prevention of gastrointestinal ulcers caused by the use of non-selective non-steroidal anti-inflammatory drugs in patients at higher risk of gastrointestinal complications requiring long-term NSAID treatment.Table. enteric 40 mg: Peptic ulcer of the stomach and duodenum. Moderate and severe reflux oesophagitis. eradicationHelicobacter pylori in combination with antibacterial treatment in patients with peptic ulcer disease. Zollinger-Ellison syndrome and other diseases involving excessive secretion of hydrochloric acid.

1 tabl enteric contains 20 mg or 40 mg pantoprazole.

A drug that inhibits the secretion of hydrochloric acid in the parietal cells of the stomach as a result of selective blocking of H activity⁺/ K⁺-ATP-azy (the so-called proton pump). The effect of the drug depends on the dose and leads to inhibition of both basal secretion and stimulated secretion (regardless of the type of stimulus). It reduces the acidity of gastric contents and, secondarily, in a reversible manner, increases gastrin secretion to an extent proportional to the decrease in acidity. After oral administration, Pantoprazole is rapidly absorbed from the gastrointestinal tract, reaching a maximum concentration in the blood after 2-2.5 h. The bioavailability is about 77%, the food does not reduce the bioavailability, it can only delay the absorption of the drug. About 98% is bound to plasma proteins. It is metabolized in the liver, excreted in about 80% by the kidneys in the form of metabolites, the remaining part is excreted in the faeces. T_0,5 in the elimination phase it is about 1 hour.

Hypersensitivity to the components of the preparation. Simultaneous treatment with atazanavir. In patients with moderate or severe hepatic and renal impairment, the preparation should not be used in combination with antibiotics for eradicationHelicobacter pylori (no data on the efficacy and safety of the preparation in this group of patients). Children.

In patients with Zollinger-Ellison syndrome and with hydrochloric acid hypersecretion using long-term treatment with Pantoprazole, decreased absorption of vitamin VI may occur. B₁₂what is caused by hypochlorhydria or achlorhydria. In the prevention of gastrointestinal ulcers caused by the use of NSAIDs, pantoprazole should only be used in patients requiring continuous treatment with NSAIDs and an increased risk of gastrointestinal complications (eg older age, gastric or duodenal ulcer, upper bleeding) gastrointestinal tract). Do not use pantoprazole 40 mg in mild gastrointestinal disorders, ie functional dyspepsia.

During pregnancy and breastfeeding, use only if the expected benefit to the mother outweighs the potential risk to the fetus or fed child.

Common: Headache, epigastric pain, diarrhea, constipation, bloating. Uncommon: dizziness, blurred vision (blurred vision), nausea, vomiting, allergic reactions (pruritus, rash). Rare: dry mouth, joint pain. Very rare: leukopenia, thrombocytopenia, anaphylactic reactions including anaphylactic shock, depression, severe liver cell damage leading to jaundice with or without hepatic failure, urticaria, angioedema, Stevens-Johnson syndrome, erythema multiforme, toxic epidermal necrolysis, hypersensitivity for light, muscle pain, interstitial nephritis, peripheral edema, increased activity of liver enzymes (transaminases, γ-glutamyltransferases), increased triglycerides, increased body temperature. Treatment with pantoprazole may lead to a slight increase in the risk of gastrointestinal infections caused by microorganisms such as:Salmonella andCampylobacter.

Orally. Adults. Mild GERD: 20 mg daily for 2-4 weeks; if necessary, continue for another 4 weeks; Recurrent symptoms can be controlled with 20 mg daily if necessary ("on demand" tablet). Long-term treatment and prevention of recurrent reflux oesophagitis: 20 mg per day; in case of relapse, the dose may be increased to 40 mg daily. Prevention of gastric and duodenal ulcers caused by the use of non-selective NSAIDs in patients at risk groups requiring constant treatment: 20 mg per day. Peptic ulcer: 40 mg daily for 4 weeks; if necessary, continue for 4 weeks. Duodenal ulcer: 40 mg daily for 2 weeks; if necessary, continue for another 2 weeks. Moderate and severe reflux oesophagitis: 40 mg daily for 4 weeks; if necessary, continue for another 4 weeks. EradicationHelicobacter pylori: 40 mg twice daily for 7 days in combination with antimicrobial therapy (amoxicillin 1 g twice daily and Clarithromycin 500 mg twice daily or clarithromycin 250-500 mg twice daily and Metronidazole 400-500 mg 2 times per day) daily or Amoxicillin 1g twice daily and metronidazole 400-500 mg twice daily); if necessary, you can continue treatment for the Next 7 days. Zollinger-Ellison syndrome and other conditions with excessive secretion of hydrochloric acid: individually, initially 80 mg per day, the dose can be increased above 160 mg daily, doses above 80 mg per day administered in two doses; the maximum duration of use is not specified. Elderly patients should not receive a dose higher than 40 mg daily (with the exception of combination therapy for eradicationH. pylori). In patients with impaired renal function, a dose of more than 40 mg per day should not be used. In patients with severe hepatic impairment, a dose greater than 20 mg daily or 40 mg every other day should not be used.
The tablets should be taken 1 hour before meals with water. The tablets should not be chewed or chewed.